Tips for Regulatory Inspections & Enforcement Actions

Upon internal audits and routine inspections, staff noticed an increase in out-of-specification (OOS) results in the stability testing of a specific drug product. The OOS results were not just isolated…

The incident began when quality control (QC) analysts noted discrepancies in the batch records submitted for review. The specific symptoms included:Click to read the full article.

Detecting the early signs of potential GMP violations is crucial for maintaining compliance. In this case, symptoms included discrepancies between recorded batch production data and real-time logs. Quality Control (QC)…

Symptoms indicating potential issues with laboratory controls can manifest in several forms. Common signs include:Click to read the full article.

The first indication of a potential issue in this pharmaceutical facility came from multiple employee reports concerning unusual rodent activity in both the manufacturing and warehouse areas. Inspection of the…

The initial signs of contamination in high-potency pharmaceutical products often manifest through unexpected deviations during in-process testing or through batch recall notices. In our case study, manufacturing operators noticed that…

Case Study: Addressing Product Release Without Adequate Investigation In the context of pharmaceutical manufacturing, the integrity of the quality management system is paramount. A leading multinational pharmaceuticals company faced a…

In our case study example, symptoms initially manifested when multiple batches of an active pharmaceutical ingredient (API) failed to meet predefined quality specifications during routine testing. The following signals were…

The scenario began with increasing reports from the manufacturing floor about non-compliance related to batch release and deviations from standard operating procedures (SOPs). Key symptoms included:Click to read the full…

The pharmaceutical company in this case study experienced a series of symptoms indicating potential data management issues:Click to read the full article.

In the weeks leading up to the regulatory intervention, several key symptoms indicated potential lapses in the manufacturing process:Click to read the full article.

The first signs of problems often arise on the production floor or within quality control labs. In this case, signs included:Click to read the full article.